Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes.
Jiqian JiangYan WangDan LiuXiaoyu WangYingqiao ZhuJuan TongErling ChenLei XueNa ZhaoTingting LiangChang-Cheng ZhengPublished in: ImmunoTargets and therapy (2023)
This study indicated that selinexor can synergistically enhance the antileukemia activity of venetoclax in AML cells in vitro by inhibiting glycolytic function and downregulating DNA replication-related genes. Based on our experimental data, combining selinexor with venetoclax is an appropriate advanced treatment option for AML patients.
Keyphrases
- end stage renal disease
- acute myeloid leukemia
- chronic lymphocytic leukemia
- signaling pathway
- induced apoptosis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- poor prognosis
- peritoneal dialysis
- prognostic factors
- genome wide
- allogeneic hematopoietic stem cell transplantation
- cell cycle arrest
- gene expression
- electronic health record
- big data
- dna methylation
- cell death
- endoplasmic reticulum stress
- binding protein
- artificial intelligence
- transcription factor
- deep learning
- bioinformatics analysis